Enhancing Data Quality in Clinical Trials: Cross-Company Validation of the Open-Source Clinical Trial Anomaly Spotter (CTAS)
CTAS is a valuable tool for timely detection of outliers in clinical data, suitable for integration into risk-based strategies. Choosing the appropriate site anomaly scoring method is crucial for handling sites with fewer subjects effectively.
Authors
- Frederik Collin
- Pekka Tiikkainen
- Björn Koneswarakantha (ORCID: https://orcid.org/0000-0003-4585-7799)
Institutions
- Roche (Switzerland) (CH)
- Boehringer Ingelheim (Germany) (DE)
- Bayer (Finland) (FI)
Publication Details
- Journal
- Therapeutic Innovation & Regulatory Science
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s43441-026-00950-y
- Primary Topic
- Anomaly Detection Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00